One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism

Mostrar otras versiones (1)

BACKGROUND: Secondary hyperparathyroidism (sHPT), a common complication of chronic kidney disease, is characterized by elevated serum parathyroid hormone (PTH). Etelcalcetide is an intravenous calcimimetic that increases sensitivity of the calcium-sensing receptor to calcium and decreases PTH secret...

Descripción completa

Detalles Bibliográficos
Autores principales: Bushinsky, David A, Chertow, Glenn M, Cheng, Sunfa, Deng, Hongjie, Kopyt, Nelson, Martin, Kevin J, Rastogi, Anjay, Ureña-Torres, Pablo, Vervloet, Marc, Block, Geoffrey A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7538239/
https://www.ncbi.nlm.nih.gov/pubmed/30859218
http://dx.doi.org/10.1093/ndt/gfz039

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7538239/
https://www.ncbi.nlm.nih.gov/pubmed/30859218
http://dx.doi.org/10.1093/ndt/gfz039

Ejemplares similares